Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following represents a first-line evidence-based pharmacologic intervention for a child with nocturnal enuresis?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 223 - 232Publisher: Cambridge University PressPrint publication year: 2023
References
Caldwell, P. H. Y., Sureshkumar, P., Wong, W. C. F. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev 2016; 2016(1): CD002117. https://doi.org/10.1002/14651858.CD002117.pub2Google Scholar
Dossche, L., Michelet, R., de Bruyne, P., et al. Desmopressin oral lyophilisate in young children: new insights in pharmacokinetics and pharmacodynamics. Arch Dis Childhood 2021; 106: 597–602. https://doi.org/10.1136/archdischild-2019-318225Google Scholar
Findling, R. L., Candler, S. A., Nasser, A. F., et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs 2021; 35(6): 643–53. https://doi.org/10.1007/s40263-021-00825-wGoogle Scholar
Glazener, C. M. A., Evans, J. H. C. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2002; 2010(1): CD002112. https://doi.org/10.1002/14651858.CD002112Google Scholar
Johnson, J. K., Liranso, T., Saylor, K., et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord 2020; 24(2): 348–58. https://doi.org/10.1177/1087054719836159CrossRefGoogle ScholarPubMed
Keten, T., Aslan, Y., Balci, M., et al. Comparison of the efficacy of desmopressin fast-melting formulation and enuretic alarm in the treatment of monosymptomatic nocturnal enuresis. J Pediatr Urol 2020; 16(5): P645.E1–E7. https://doi.org/10.1016/j.jpurol.2020.07.018Google Scholar
Michelet, R., Dossche, L., van Herzeele, C. An integrated paediatric population PK/PD analysis of dDAVP: how do PK differences translate to clinical outcomes? Clin Pharmacokin 2020; 59(1): 81–96. https://doi.org/10.1007/s40262-019-00798-6Google Scholar
Mikkelsen, E. J. Elimination disorders. In Dulcan, M. (ed.), Dulcan’s Textbook of Child and Adolescent Psychiatry, 3rd edn. Washington D.C.: American Psychiatric Publishing, 2021.Google Scholar
Nasser, A., Hull, J. T., Liranso, T., et al. The effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials. Neuropsychiatric Dis Treat 2021; 17: 1751–62. https://doi.org/10.2147/NDT.S312011Google Scholar
Rittig, S., Knudsen, U. B., Norgaard, J. P., Pedersen, E. B., Djurhuus, J. C. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol Renal Fluid Electrolyte Physiol 1989; 256(4): F664–71. https://doi.org/10.1152/ajprenal.1989.256.4.f664Google Scholar
Shaffer, D., Costello, A. J., Hill, I. D. Control of enuresis with imipramine. Arch Dis Childhood 1968; 43(232): 665. https://doi.org/10.1136/adc.43.232.665Google Scholar
Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., Maletic, V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol 2020; 12: 285–300. https://doi.org/10.2147/JEP.S256586Google Scholar